CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value
Chosen cutoff for cytokeratin 19 fragment antigen (CYFRA 21-1) as a tumor biomarker considerably influences its diagnostic and prognostic usefulness. The aim of the present study is to determine an optimal cutoff value for diagnostic validity of CYFRA 21-1 by Lumipulse ® technology in patients with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2020-10-01
|
| Series: | Advances in Laboratory Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/almed-2020-0005 |
| _version_ | 1827916298750787584 |
|---|---|
| author | Garcia-Valdecasas Gayo Sonsoles Ruiz-Alvarez Maria Jesus Gonzalez-Gay Daniel Ramos-Corral Raquel Marquez-Lietor Eva Del Amo Nazaret Plata Maria del Carmen Guillén-Santos Raquel Arribas Ignacio Cava-Valenciano Fernando |
| author_facet | Garcia-Valdecasas Gayo Sonsoles Ruiz-Alvarez Maria Jesus Gonzalez-Gay Daniel Ramos-Corral Raquel Marquez-Lietor Eva Del Amo Nazaret Plata Maria del Carmen Guillén-Santos Raquel Arribas Ignacio Cava-Valenciano Fernando |
| author_sort | Garcia-Valdecasas Gayo Sonsoles |
| collection | DOAJ |
| description | Chosen cutoff for cytokeratin 19 fragment antigen (CYFRA 21-1) as a tumor biomarker considerably influences its diagnostic and prognostic usefulness. The aim of the present study is to determine an optimal cutoff value for diagnostic validity of CYFRA 21-1 by Lumipulse
® technology in patients with suspected cancer and also to determine if CYFRA 21-1 levels provide prognostic value. |
| first_indexed | 2024-03-13T03:13:11Z |
| format | Article |
| id | doaj.art-982c08d81cda467fa39bf2018dbdc8d1 |
| institution | Directory Open Access Journal |
| issn | 2628-491X |
| language | English |
| last_indexed | 2024-03-13T03:13:11Z |
| publishDate | 2020-10-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Advances in Laboratory Medicine |
| spelling | doaj.art-982c08d81cda467fa39bf2018dbdc8d12023-06-26T10:46:03ZengDe GruyterAdvances in Laboratory Medicine2628-491X2020-10-0114160510.1515/almed-2020-0005CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic valueGarcia-Valdecasas Gayo Sonsoles0Ruiz-Alvarez Maria Jesus1Gonzalez-Gay Daniel2Ramos-Corral Raquel3Marquez-Lietor Eva4Del Amo Nazaret5Plata Maria del Carmen6Guillén-Santos Raquel7Arribas Ignacio8Cava-Valenciano Fernando9Central Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainDepartment of Clinical Chemistry, Ramón y Cajal University Hospital, San Sebastian de los Reyes, Madrid, SpainCentral Laboratory BR Salud, Department of Clinical Chemistry, Infanta Sofia University Hospital, San Sebastian de los Reyes, Madrid, SpainChosen cutoff for cytokeratin 19 fragment antigen (CYFRA 21-1) as a tumor biomarker considerably influences its diagnostic and prognostic usefulness. The aim of the present study is to determine an optimal cutoff value for diagnostic validity of CYFRA 21-1 by Lumipulse ® technology in patients with suspected cancer and also to determine if CYFRA 21-1 levels provide prognostic value.https://doi.org/10.1515/almed-2020-0005bladder cancercutoffcyfra 21-1lung cancernon-small cell lung cancer (nsclc)prognosistumor marker |
| spellingShingle | Garcia-Valdecasas Gayo Sonsoles Ruiz-Alvarez Maria Jesus Gonzalez-Gay Daniel Ramos-Corral Raquel Marquez-Lietor Eva Del Amo Nazaret Plata Maria del Carmen Guillén-Santos Raquel Arribas Ignacio Cava-Valenciano Fernando CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value Advances in Laboratory Medicine bladder cancer cutoff cyfra 21-1 lung cancer non-small cell lung cancer (nsclc) prognosis tumor marker |
| title | CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| title_full | CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| title_fullStr | CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| title_full_unstemmed | CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| title_short | CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| title_sort | cyfra 21 1 in patients with suspected cancer evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value |
| topic | bladder cancer cutoff cyfra 21-1 lung cancer non-small cell lung cancer (nsclc) prognosis tumor marker |
| url | https://doi.org/10.1515/almed-2020-0005 |
| work_keys_str_mv | AT garciavaldecasasgayosonsoles cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT ruizalvarezmariajesus cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT gonzalezgaydaniel cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT ramoscorralraquel cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT marquezlietoreva cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT delamonazaret cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT platamariadelcarmen cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT guillensantosraquel cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT arribasignacio cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue AT cavavalencianofernando cyfra211inpatientswithsuspectedcancerevaluationofanoptimalcutofftoassessthediagnosticefficacyandprognosticvalue |